Plans to promote participant retention and complete follow-up {18b}
This trial consists in a single administration of midazolam or dexmedetomidine following the randomization. Patients will be monitored during the day of the sedation until discharge from the PACU. All study patients, except those that withdraw consent for the study, will be called 24 h after the sedation to complete the assessment of the post-sedation period.